Onconetix (ONCO) Asset Writedowns and Impairment (2023 - 2026)

Onconetix (ONCO) has reported Asset Writedowns and Impairment for 3 consecutive years, with $8.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $18.4 million (changed N/A YoY), while the FY2025 annual figure was $11.5 million, up 226.05% from the prior year.
• Asset Writedowns and Impairment advanced to $8.1 million in Q1 2026 per ONCO's latest filing, from $1.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $14.7 million in Q4 2023 and bottomed at -$3.2 million in Q3 2023.
• Historically, Asset Writedowns and Impairment has averaged $5.1 million across 3 years, with a median of $3.5 million in 2023.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 194.29% in 2024 and fell as far as 100.0% in 2024.
• Onconetix's Asset Writedowns and Impairment stood at $14.7 million in 2023, then sank by 100.0% to $1.0 in 2024, then soared by 813399900.0% to $8.1 million in 2026.
• Business Quant data shows ONCO's Asset Writedowns and Impairment at $8.1 million in Q1 2026, $1.0 in Q4 2024, and $10.3 million in Q2 2024.